CROWN BIOSCIENCE NETHERLANDS BV

Their core work

Crown Bioscience Netherlands is a preclinical contract research organization (CRO) based in Leiden, specializing in patient-derived xenograft (PDX) cancer models and translational oncology services. They maintain biobanks of tumor models used by pharmaceutical companies and academic researchers to test drug candidates before clinical trials. Their work spans drug safety assessment through quantitative systems pharmacology, 3D cancer immunotherapy screening platforms, and drug repurposing strategies. As part of the global Crown Bioscience group, they bridge commercial drug development with EU-funded research infrastructure.

What they specialise in

How they've shifted over time

Crown Bioscience's early H2020 engagement (2017-2018) centered on computational drug safety — systems pharmacology, PBPK modelling, and translational toxicology through TransQST. From 2018 onward, their focus shifted decisively toward hands-on preclinical oncology: xenograft biobanking infrastructure (EDIReX), targeted drug discovery via ubiquitin ligase pathways (TRIM-NET), and drug repurposing strategies (DRUGtrain). This evolution shows a move from computational safety modelling toward experimental cancer biology and infrastructure provision.

Crown Bioscience is consolidating its position as a commercial provider of preclinical cancer models and training host for early-career drug discovery researchers, making them a strong partner for translational oncology consortia.

How they like to work

Crown Bioscience primarily joins consortia as a specialist participant (3 of 5 projects), contributing commercial preclinical capabilities to larger academic-led networks. They coordinated one project (3DPD), a focused PhD placement, suggesting they prefer contributing domain expertise over managing large consortia. With 55 unique partners across 13 countries, they are well-connected and comfortable in large multi-national teams — typical of an industry partner embedded in the European research infrastructure ecosystem.

With 55 consortium partners spread across 13 countries, Crown Bioscience has built a broad European network, particularly within the oncology and drug development research communities. Their participation in large infrastructure projects like EDIReX and training networks like TransQST connects them to major cancer research centers and pharmaceutical research groups across the EU.

What sets them apart

Crown Bioscience occupies a rare niche as a commercial SME that provides industrial-grade preclinical cancer models directly within EU research consortia. Unlike academic partners who build models for single studies, they maintain standardized, reproducible PDX biobanks at commercial scale — a resource most consortia cannot replicate internally. Their dual role as both a service provider and a training host for PhD and early-career researchers makes them an unusually versatile industry partner for translational oncology projects.

Highlights from their portfolio

• EDIReX
  Their largest funded project (EUR 254,937), providing trans-national access to Europe's distributed patient-derived xenograft infrastructure — directly aligned with their core commercial offering.
• 3DPD
  Their only coordinated project, embedding a PhD researcher in their commercial environment to develop 3D cancer immunotherapy drug screening — a rare industry-led MSCA action.
• TransQST
  Their highest single funding (EUR 325,354) in a large-scale systems toxicology initiative, representing their computational pharmacology capabilities.